# Primary Radiotherapy In MEtastatic Lung Cancer

Source: https://onco.cc/trials/nct07135882/  
OnCo record `nct07135882` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Trans Tasman Radiation Oncology Group, not yet recruiting.

## Summary

Primary Radiotherapy In MEtastatic Lung Cancer is a phase 3, randomised interventional study registered as NCT07135882 by Trans Tasman Radiation Oncology Group, with a registry enrolment figure of 420 participants, started 2026-08-25 and due to reach its primary completion in 2030-12-31. Interventions recorded: Radiotherapy followed by chemotherapy; Standard of Care (SOC). Conditions listed: Carcinoma, Non-Small-Cell Lung (NSCLC). Primary outcome: Overall survival. Lung eligibility wording from the registry: "* Newly diagnosed metastatic (stage IV) NSCLC, not amenable to curative surgery or curative radiotherapy". Sites: Australia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: PRIME-Lung
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07135882
- Phase: 3
- Setting: A Randomised Phase III Trial of Up-front Radiotherapy With Standard-of-care Systemic Therapy in Advanced Lung Cancer
- Sponsor: Trans Tasman Radiation Oncology Group
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT07135882: https://clinicaltrials.gov/study/NCT07135882

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- companies: [TROG Cancer Research](https://onco.cc/companies/trog/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07135882.json